Meet Dr. Brandon Kirsch

Board-Certified Dermatologist

Brandon Kirsch, MD, FAAD started his career as a lawyer and holds law degrees from the University of Western Ontario (LL.B.) and Georgetown University (LL.M. Securities and Financial Regulation). He completed medical school at Brown University, an internship at the Mayo Clinic and dermatology residency at the University of North Carolina. He is licensed to practice law in both New York and Ontario, Canada and holds medical licenses in California, Colorado, Florida and North Carolina. Dr. Kirsch is honored to have received support for his education from the American Mensa Cooper Memorial Scholarship, Alpert Medical School Carpenter Traveling Fellowship, Walsh Medical Scholarship, Ontario Law Foundation Graduate Fellowship and the Western Scholarship of Distinction.

In addition to a busy clinical practice, and serving as Chief of Dermatology at the Naples Community Hospital, Dr. Kirsch is the President and Chief Executive Officer at ClearifiRx.com, a dermatologist-led online platform providing personalized prescriptions to treat skin conditions. He has interests in therapeutic drug development and medical innovation. In partnership with the Mayo Clinic, he filed to patent a novel topical composition for the treatment of melasma. He also received a grant from the Mayo Clinic to complete an investigator-initiated pilot study of this formulation.

Dr. Kirsch was previously an Assistant Clinical Professor of Dermatology at the University of Colorado and Medical Director and Vice President of Clinical Development at Brickell Biotech, Inc. At Brickell, Dr. Kirsch provided leadership and strategic direction for the clinical science team. In his role, he had primary responsibility for overseeing development programs from late preclinical to registration Phase 3 randomized studies. Dr. Kirsch has been published in the Journal of the American Medical Association, Journal of the American Academy of Dermatology, Journal of Drugs in Dermatology, Journal of Clinical and Aesthetic Dermatology, Dermatology Times, The Journal of Investigative Dermatology, The Journal of Cancer Immunology Research, The Canadian Journal of Neurological Sciences, Reason, The Wall Street Journal, The Toronto Star, The Providence Journal, and The Jacksonville Times-Union.

View Dr. Kirsch's CV

MEDICAL PUBLICATIONS AND ABSTRACTS

Kirsch, Brandon, Stacy Smith, Joel Cohen, Janet DuBois, Lawrence Green, Leslie Baumann, Neal Bhatia et al. "Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial." Journal of the American Academy of Dermatology (2020).

Kirsch, B., Hoesly, P. and Sluzevich, J., 2018. Efficacy and tolerability of combination tazarotene, azelaic acid, tacrolimus, and zinc oxide for the treatment of melasma: 7101. Journal of the American Academy of Dermatology, 79(3).

Kirsch, B. M., Burke, L., Hobart, J., Angulo, D., & Walker, P. S. (2018). The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content. Journal of drugs in dermatology: JDD, 17(7), 707-714.

Kirsch, Brandon, and Brian C. Drolet. "The National Resident Matching Program and Competition for Employment." JAMA 319, no. 17 (2018): 1823-1824.

Xu S, Allred J, Kirsch B, Raff A, Anderson RR, Ju W. (2016) Training the Next Generation of Innovators in Dermatology. J Invest Dermatol. 2016; 136(11):2113-2115.

Kirsch, B. M. & Cappel, M. A. (2015). Acute generalized exanthematous pustulosis induced by mifepristone. JAAD Case Reports, 1(4), 191-195.

Kirsch, B. MD & Sluzevich, J. MD. The generalized rash: part I. Differential diagnosis; The generalized rash: part II. Diagnostic approach. Frank J. Domino, MD, Robert A. Baldor MD, FAAFP, eds. 2015. 5-Minute Clinical Consult - 24th Ed. Philadelphia, PA. Lippincott Williams & Wilkins Health.

Joseph, R.W., Goedjen B., Gordon, M., Kirsch, B., Gilstrap, C., Bagaria, S. & Jambusaria, A. (2014). Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015; 3(1), 18-22.

Kirsch, B., Grant-Kels, J.M. & Bercovitch, L. (2013). The ethics of “Top Doctor” awards: A tangled web. Journal of the American Academy of Dermatology, 69(5), 792-794.

Kirsch, B. & Bernstein, M. (2012). Ethical challenges with awake craniotomy for tumor. The Canadian Journal of Neurological Sciences, 39(1), 78-82.

MEDICAL PRESENTATIONS
Kirsch, B, Burke, L, Hobart, J, Angulo, D, Walker, P. Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax): Content Development and Measurement Property Testing. (2018). Presented at the South Beach Symposium; Miami, FL. 03/01/2018.

Smith, S, Kirsch, B, Walker, P. A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 5%, 10% and 15% Topically Applied Sofpironium Bromide Gel in Subjects with Axillary Hyperhidrosis. Presented at the Late-breaking Research Forum of the 76th Annual Meeting of the American Academy of Dermatology; San Diego, CA. 02/22/2018.

Kirsch, B, Hoesly, P, Sluzevich, J. Efficacy and Tolerability of Combination Tazarotene, Azelaic Acid, Tacrolimus and Zinc Oxide for the Treatment of Melasma. (2018). Presented at the 76th Annual Meeting of the American Academy of Dermatology; San Diego, CA. 02/22/2018.

Training the Next Generation of Innovators in Dermatology. Panelist at the Dermatology Entrepreneurship Conference Residents’ Lunch; San Diego, CA. 02/21/2018.

Teachers and Trainees Luncheon: Promoting Innovation in Dermatology. Panelist at the Dermatology Entrepreneurship Conference Residents’ Lunch; Orlando, FL. 03/03/2017.

Careers in Product Innovation. Panelist at the Dermatology Entrepreneurship Conference Residents’ Lunch; Washington, D.C. 03/04/2016.

Tumoral Melanosis. Dermatopathology Trainee World Cup. Presented at the 19th Joint Meeting of the International Society of Dermatopathology; Washington, D.C. 03/02/2016.

Oral Therapies for the Treatment of Hyperpigmentation. Presented at the Cosmetic Surgery Forum; Las Vegas, NV. 12/02/15.

A Fighter’s Guide to Resident Entrepreneurship. Presented at the Advancing Innovation in Dermatology Journal Club as the inaugural resident case study. Virtual. 11/18/2015.

Acute Generalized Exanthematous Pustulosis Induced by Mifepristone. Presented at the Florida Society of Dermatology and Dermatologic Surgery Annual Meeting; Boca Raton, FL. 04/18/2015.

Illuminate: Advanced Skin Lightening Composition. Poster presentation at the Dermatology Entrepreneurship Conference; San Francisco, CA. 03/19/2015.

Treatment of Onychomycosis with Photodynamic Therapy. Presented at Orlando Dermatology Aesthetic and Clinical Conference; Orlando, FL. 01/17/2014.

PATENTS
Skin Care Composition: International Application (PCT) for Filing in US Receiving Office
- Method for lightening skin color without atrophy or paradoxical hyperpigmentation

IRB PROTOCOLS
An Open-Label Pilot Study Evaluating the Effectiveness and Tolerability of a Topical Skin Care Composition Therapy (2013-MCN-333) for the Treatment of Melasma

RESEARCH GRANTS AWARDED
Mayo Clinic Accelerate Innovation Grant

VOLUNTEERISM
Advancing Innovation in Dermatology: Education Committee Founder

AREAS OF INTEREST
Acne/rosacea, pigmentary disorders, psoriasis, rashes, hyperhidrosis, hair loss, cosmetics/aging (lasers, neuromodulators and fillers), preventative and holistic medicine, and skin cancer.